An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors


I'm Interested

Trial ID: NCT04250155


This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.

Official Title

A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Stanford Investigator(s)

Saad A. Khan, MD
Saad A. Khan, MD

Assistant Professor of Medicine (Oncology)


Key General Inclusion Criteria

   - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

   - Life expectancy >/= 12 weeks

   - Adequate hematologic and end-organ function

   - For participants receiving therapeutic anticoagulation: stable anticoagulant regimen

   - Negative serum pregnancy test for women of childbearing potential

   - Histologically confirmed locally advanced, recurrent, or metastatic incurable solid
   tumor malignancy

   - Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

   - Availability of representative tumor specimens

Key General Exclusion Criteria

   - Pregnant or breastfeeding, or intending to become pregnant during the study

   - Significant cardiovascular disease

   - Current treatment with medications that prolong the QT interval

   - Known clinically significant liver disease

   - Poorly controlled Type 2 diabetes mellitus

   - Symptomatic, untreated, or actively progressing CNS metastases

   - History of leptomeningeal disease

   - History of malignancy other than disease under study within 3 years prior to screening

   - Active or history of autoimmune disease or immune deficiency

   - Active tuberculosis, hepatitis B, hepatitis C, or known/suspected Epstein Barr virus

   - Positive for HIV infection

   - Prior allogeneic stem cell or solid organ transplantation


drug: XmAb24306

drug: Atezolizumab

drug: XmAb24306


I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Team Phase 1

New Trial Alerts

Receive email alerts when trials open to patients.